To include your compound in the COVID-19 Resource Center, submit it here.

Exiting Covagen

How investors fared in takeout of mAb platform play Covagen by J&J

Terms of Johnson & Johnson's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size and investor returns for private, venture-backed European biotechs.

Covagen is developing a pipeline of multi-specific FynomAbs, which are fusions of antibodies and Fynomers. Fynomers are small proteins derived from the SH3 domain of FYN proto-oncogene src family tyrosine kinase (FYN) that can

Read the full 751 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE